Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma

Our recent study demonstrated that a novel proteasome inhibitor NPI-0052 triggers apoptosis in multiple myeloma (MM) cells, and importantly, that is distinct from bortezomib (Velcade) in its chemical structure, effects on proteasome activities, and mechanisms of action. Here, we demonstrate that com...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Chauhan, Dharminder, Singh, Ajita, Brahmandam, Mohan, Podar, Klaus, Hideshima, Teru, Richardson, Paul, Munshi, Nikhil, Palladino, Michael A., Anderson, Kenneth C.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2008
Gaiak:
Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2214767/
https://ncbi.nlm.nih.gov/pubmed/18006697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-08-105601
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak